Get the latest tech news
Hallucinations in AI: How GSK is addressing a critical problem in drug development
Hallucinations are a persistent problem in healthcare. Here's how GSK is using test-time compute scaling to improve its gen AI systems.
This makes hallucinations in large language models (LLMs) a critical issue for companies like GSK, where gen AI is applied to tasks such as scientific literature review, genomic analysis and drug discovery. According to Kim Branson, SvP of AI and machine learning (ML) at GSK, these techniques help ensure that agents are “robust and reliable,” while enabling scientists to generate actionable insights more quickly. Maintaining a leading edge in compute innovations and sophisticated inference techniques not only addresses current challenges, but also lays the groundwork for breakthroughs in drug discovery, patient care and beyond.
Or read this on Venture Beat
